A model for early prediction and prognosis evaluation of sepsis based on plasma proteomics

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200064742

Enrollment

Unknown

Registered

2022-10-15

Start date

2022-10-15

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Interventions

Sepsis group:none

healthy control:none

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Sepsis (sepsis 3.0 standard, infection+SOFA score>2); 2. Age: >= 18 years,48 hours.

Exclusion criteria

Exclusion criteria: 1. Malignant tumors; 2. Congenital immune deficiency; 3. Hematological system diseases; 4. Pregnancy, lactation, pregnancy; 5. Immunosuppressive status: Chemotherapy or treatment with hydrocortisone>400mg or methylprednisolone>80mg or dexamethasone>15mg or equivalent doses of other steroid hormones in the past 15 days; 6. Organ transplantation; 7. Chronic viral infections (hepatitis, HIV), liver cirrhosis; 8. Chronic renal insufficiency; 9. Autoimmune diseases.

Design outcomes

Primary

Measure	Time frame
28-day mortality;	—

Secondary

Measure	Time frame
90-day mortality;plasma protein;	—

Countries

China

Contacts

Public ContactDechang Chen

Ruijin Hospital,Shanghai Jiaotong University School of Medicine

chendechangsh@hotmail.com+86 18918520002

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026